Global Clinical Oncology Next Generation Sequencing (NGS)

Clinical Oncology Next Generation Sequencing (NGS) Comprehensive Study by Type (NGS Pre-Sequencing, Sequencing, NGS Data Analysis, Primary, Secondary & Tertiary Data Analysis), Application (Academic & Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities), Category (Sequencing platform, Kits & Reagents), Technology (Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing) Players and Region - Global Market Outlook to 2028

Clinical Oncology Next Generation Sequencing (NGS) Market by XX Submarkets | Forecast Years 2023-2028 | CAGR: 14.6%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Clinical Oncology Next Generation Sequencing (NGS)
Next Generation Sequencing is a highly sensitive method for detecting mutations in samples containing as little as 5% tumor cells. It can be multiplexed, which means that multiple genes can be targeted at the same time, allowing for the detection of multiple mutations in the same assay. The specificity of the assay is increased by reading each DNA nucleotide several times (100-1000 times), this platform provides accurate, reliable data and excellent coverage. NGS innovations are now making the transition from clinical science to an environment where they can make a meaningful contribution to individual patient cancer care. The transfer of next-generation sequencing (NGS) technology from the laboratory to clinical practice is supported by compelling evidence. Until NGS technologies are completely implemented in the clinic, their potential as effective diagnostic and prognostic tools should be thoroughly investigated.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
CAGR14.6%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Clinical Oncology Next Generation Sequencing (NGS) market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Thermo Fisher Scientific (United States), Becton, Dickinson and Company (United States), Oxford Nanopore Technologies (United Kingdom), Qiagen (Germany), Myriad Genetics (United States), Illumina (United States), F. Hoffmann-La Roche (Switzerland), Perkin Elmer (United Kingdom), GATC Biotech (Germany) and Agilent Technologies (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Caris Life Sciences (United States), Macrogen (South Korea), Life Technologies (United States), DNASTAR (United States), Biomatters (New Zealand) and Partek (United States).

Segmentation Overview
AMA Research has segmented the market of Global Clinical Oncology Next Generation Sequencing (NGS) market by Type (NGS Pre-Sequencing, Sequencing, NGS Data Analysis and Primary, Secondary & Tertiary Data Analysis), Application (Academic & Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities) and Region.



On the basis of geography, the market of Clinical Oncology Next Generation Sequencing (NGS) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by , the sub-segment i.e. will boost the Clinical Oncology Next Generation Sequencing (NGS) market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Emergence of Cost-Efficient Genome Sequencing

Market Growth Drivers:
Prevalence of Cancers Including Chronic Myelogenous Leukemia and Technical Progress in NGS Platforms

Challenges:
Proper Reimbursement Mechanism and Data Storage and Computation

Restraints:
Highly Expensive Procedures and Presence of Efficient Alternatives

Opportunities:
Integration with Big Data and Analytical Platforms

Market Leaders and their expansionary development strategies
In August 2021- llumina, Inc. announced that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers but they held GRAIL as a separate company during the European Commission's ongoing regulatory review, In March 2020 - Agilent Announced its Acquisition of Resolution Bioscience (a Leading Next-Generation Sequencing (NGS)-Based Oncology Solution Provider), this Acquisition is Aimed to Strengthen Agilent’s and Leadership Position Across Cancer Diagnostics. The Combination Combines Agilent's Tissue-Based Companion Diagnostics with a Noninvasive Liquid Biopsy Platform That Enhances Cancer Diagnostics.



Key Target Audience
Pharma & Biotech Manufactures, New Entrants and Investors, Pharma & Biotech Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • NGS Pre-Sequencing
  • Sequencing
  • NGS Data Analysis
  • Primary, Secondary & Tertiary Data Analysis
By Application
  • Academic & Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
By Category
  • Sequencing platform
  • Kits & Reagents

By Technology
  • Ion Semiconductor Sequencing
  • Pyro-Sequencing
  • Synthesis Sequencing
  • Real Time Sequencing
  • Ligation Sequencing
  • Reversible Dye Termination Sequencing
  • Nano-Pore Sequencing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Cancers Including Chronic Myelogenous Leukemia
      • 3.2.2. Technical Progress in NGS Platforms
    • 3.3. Market Challenges
      • 3.3.1. Proper Reimbursement Mechanism
      • 3.3.2. Data Storage and Computation
    • 3.4. Market Trends
      • 3.4.1. Emergence of Cost-Efficient Genome Sequencing
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Clinical Oncology Next Generation Sequencing (NGS), by Type, Application, Category, Technology and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Clinical Oncology Next Generation Sequencing (NGS) (Value)
      • 5.2.1. Global Clinical Oncology Next Generation Sequencing (NGS) by: Type (Value)
        • 5.2.1.1. NGS Pre-Sequencing
        • 5.2.1.2. Sequencing
        • 5.2.1.3. NGS Data Analysis
        • 5.2.1.4. Primary, Secondary & Tertiary Data Analysis
      • 5.2.2. Global Clinical Oncology Next Generation Sequencing (NGS) by: Application (Value)
        • 5.2.2.1. Academic & Clinical Research
        • 5.2.2.2. Hospitals & Clinics
        • 5.2.2.3. Pharma & Biotech Entities
      • 5.2.3. Global Clinical Oncology Next Generation Sequencing (NGS) by: Category (Value)
        • 5.2.3.1. Sequencing platform
        • 5.2.3.2. Kits & Reagents
      • 5.2.4. Global Clinical Oncology Next Generation Sequencing (NGS) by: Technology (Value)
        • 5.2.4.1. Ion Semiconductor Sequencing
        • 5.2.4.2. Pyro-Sequencing
        • 5.2.4.3. Synthesis Sequencing
        • 5.2.4.4. Real Time Sequencing
        • 5.2.4.5. Ligation Sequencing
        • 5.2.4.6. Reversible Dye Termination Sequencing
        • 5.2.4.7. Nano-Pore Sequencing
      • 5.2.5. Global Clinical Oncology Next Generation Sequencing (NGS) Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Clinical Oncology Next Generation Sequencing (NGS) (Price)
      • 5.3.1. Global Clinical Oncology Next Generation Sequencing (NGS) by: Type (Price)
  • 6. Clinical Oncology Next Generation Sequencing (NGS): Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton, Dickinson and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Oxford Nanopore Technologies (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Qiagen (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Myriad Genetics (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Illumina (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Perkin Elmer (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GATC Biotech (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Agilent Technologies (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Clinical Oncology Next Generation Sequencing (NGS) Sale, by Type, Application, Category, Technology and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Clinical Oncology Next Generation Sequencing (NGS) (Value)
      • 7.2.1. Global Clinical Oncology Next Generation Sequencing (NGS) by: Type (Value)
        • 7.2.1.1. NGS Pre-Sequencing
        • 7.2.1.2. Sequencing
        • 7.2.1.3. NGS Data Analysis
        • 7.2.1.4. Primary, Secondary & Tertiary Data Analysis
      • 7.2.2. Global Clinical Oncology Next Generation Sequencing (NGS) by: Application (Value)
        • 7.2.2.1. Academic & Clinical Research
        • 7.2.2.2. Hospitals & Clinics
        • 7.2.2.3. Pharma & Biotech Entities
      • 7.2.3. Global Clinical Oncology Next Generation Sequencing (NGS) by: Category (Value)
        • 7.2.3.1. Sequencing platform
        • 7.2.3.2. Kits & Reagents
      • 7.2.4. Global Clinical Oncology Next Generation Sequencing (NGS) by: Technology (Value)
        • 7.2.4.1. Ion Semiconductor Sequencing
        • 7.2.4.2. Pyro-Sequencing
        • 7.2.4.3. Synthesis Sequencing
        • 7.2.4.4. Real Time Sequencing
        • 7.2.4.5. Ligation Sequencing
        • 7.2.4.6. Reversible Dye Termination Sequencing
        • 7.2.4.7. Nano-Pore Sequencing
      • 7.2.5. Global Clinical Oncology Next Generation Sequencing (NGS) Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Clinical Oncology Next Generation Sequencing (NGS) (Price)
      • 7.3.1. Global Clinical Oncology Next Generation Sequencing (NGS) by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Clinical Oncology Next Generation Sequencing (NGS): by Type(USD Million)
  • Table 2. Clinical Oncology Next Generation Sequencing (NGS) NGS Pre-Sequencing , by Region USD Million (2017-2022)
  • Table 3. Clinical Oncology Next Generation Sequencing (NGS) Sequencing , by Region USD Million (2017-2022)
  • Table 4. Clinical Oncology Next Generation Sequencing (NGS) NGS Data Analysis , by Region USD Million (2017-2022)
  • Table 5. Clinical Oncology Next Generation Sequencing (NGS) Primary, Secondary & Tertiary Data Analysis , by Region USD Million (2017-2022)
  • Table 6. Clinical Oncology Next Generation Sequencing (NGS): by Application(USD Million)
  • Table 7. Clinical Oncology Next Generation Sequencing (NGS) Academic & Clinical Research , by Region USD Million (2017-2022)
  • Table 8. Clinical Oncology Next Generation Sequencing (NGS) Hospitals & Clinics , by Region USD Million (2017-2022)
  • Table 9. Clinical Oncology Next Generation Sequencing (NGS) Pharma & Biotech Entities , by Region USD Million (2017-2022)
  • Table 10. Clinical Oncology Next Generation Sequencing (NGS): by Category(USD Million)
  • Table 11. Clinical Oncology Next Generation Sequencing (NGS) Sequencing platform , by Region USD Million (2017-2022)
  • Table 12. Clinical Oncology Next Generation Sequencing (NGS) Kits & Reagents , by Region USD Million (2017-2022)
  • Table 13. Clinical Oncology Next Generation Sequencing (NGS): by Technology(USD Million)
  • Table 14. Clinical Oncology Next Generation Sequencing (NGS) Ion Semiconductor Sequencing , by Region USD Million (2017-2022)
  • Table 15. Clinical Oncology Next Generation Sequencing (NGS) Pyro-Sequencing , by Region USD Million (2017-2022)
  • Table 16. Clinical Oncology Next Generation Sequencing (NGS) Synthesis Sequencing , by Region USD Million (2017-2022)
  • Table 17. Clinical Oncology Next Generation Sequencing (NGS) Real Time Sequencing , by Region USD Million (2017-2022)
  • Table 18. Clinical Oncology Next Generation Sequencing (NGS) Ligation Sequencing , by Region USD Million (2017-2022)
  • Table 19. Clinical Oncology Next Generation Sequencing (NGS) Reversible Dye Termination Sequencing , by Region USD Million (2017-2022)
  • Table 20. Clinical Oncology Next Generation Sequencing (NGS) Nano-Pore Sequencing , by Region USD Million (2017-2022)
  • Table 21. South America Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2017-2022)
  • Table 22. South America Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 23. South America Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 24. South America Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 25. South America Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 26. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 27. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 28. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 29. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 30. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 31. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 32. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 33. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 34. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 35. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 36. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 37. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 38. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2017-2022)
  • Table 39. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 40. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 41. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 42. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 43. China Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 44. China Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 45. China Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 46. China Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 47. Japan Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 48. Japan Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 49. Japan Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 50. Japan Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 51. India Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 52. India Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 53. India Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 54. India Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 55. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 56. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 57. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 58. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 59. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 60. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 61. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 62. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 63. Australia Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 64. Australia Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 65. Australia Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 66. Australia Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 70. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 71. Europe Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2017-2022)
  • Table 72. Europe Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 73. Europe Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 74. Europe Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 75. Europe Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 76. Germany Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 77. Germany Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 78. Germany Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 79. Germany Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 80. France Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 81. France Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 82. France Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 83. France Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 84. Italy Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 85. Italy Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 86. Italy Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 87. Italy Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 88. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 89. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 90. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 91. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 92. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 93. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 94. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 95. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 96. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 97. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 98. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 99. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 100. MEA Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2017-2022)
  • Table 101. MEA Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 102. MEA Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 103. MEA Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 104. MEA Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 105. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 106. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 107. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 108. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 109. Africa Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 110. Africa Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 111. Africa Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 112. Africa Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 113. North America Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2017-2022)
  • Table 114. North America Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 115. North America Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 116. North America Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 117. North America Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 118. United States Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 119. United States Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 120. United States Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 121. United States Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 122. Canada Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 123. Canada Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 124. Canada Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 125. Canada Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 126. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2017-2022)
  • Table 127. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2017-2022)
  • Table 128. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2017-2022)
  • Table 129. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2017-2022)
  • Table 130. Clinical Oncology Next Generation Sequencing (NGS): by Type(USD/Units)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Clinical Oncology Next Generation Sequencing (NGS): by Type(USD Million)
  • Table 142. Clinical Oncology Next Generation Sequencing (NGS) NGS Pre-Sequencing , by Region USD Million (2023-2028)
  • Table 143. Clinical Oncology Next Generation Sequencing (NGS) Sequencing , by Region USD Million (2023-2028)
  • Table 144. Clinical Oncology Next Generation Sequencing (NGS) NGS Data Analysis , by Region USD Million (2023-2028)
  • Table 145. Clinical Oncology Next Generation Sequencing (NGS) Primary, Secondary & Tertiary Data Analysis , by Region USD Million (2023-2028)
  • Table 146. Clinical Oncology Next Generation Sequencing (NGS): by Application(USD Million)
  • Table 147. Clinical Oncology Next Generation Sequencing (NGS) Academic & Clinical Research , by Region USD Million (2023-2028)
  • Table 148. Clinical Oncology Next Generation Sequencing (NGS) Hospitals & Clinics , by Region USD Million (2023-2028)
  • Table 149. Clinical Oncology Next Generation Sequencing (NGS) Pharma & Biotech Entities , by Region USD Million (2023-2028)
  • Table 150. Clinical Oncology Next Generation Sequencing (NGS): by Category(USD Million)
  • Table 151. Clinical Oncology Next Generation Sequencing (NGS) Sequencing platform , by Region USD Million (2023-2028)
  • Table 152. Clinical Oncology Next Generation Sequencing (NGS) Kits & Reagents , by Region USD Million (2023-2028)
  • Table 153. Clinical Oncology Next Generation Sequencing (NGS): by Technology(USD Million)
  • Table 154. Clinical Oncology Next Generation Sequencing (NGS) Ion Semiconductor Sequencing , by Region USD Million (2023-2028)
  • Table 155. Clinical Oncology Next Generation Sequencing (NGS) Pyro-Sequencing , by Region USD Million (2023-2028)
  • Table 156. Clinical Oncology Next Generation Sequencing (NGS) Synthesis Sequencing , by Region USD Million (2023-2028)
  • Table 157. Clinical Oncology Next Generation Sequencing (NGS) Real Time Sequencing , by Region USD Million (2023-2028)
  • Table 158. Clinical Oncology Next Generation Sequencing (NGS) Ligation Sequencing , by Region USD Million (2023-2028)
  • Table 159. Clinical Oncology Next Generation Sequencing (NGS) Reversible Dye Termination Sequencing , by Region USD Million (2023-2028)
  • Table 160. Clinical Oncology Next Generation Sequencing (NGS) Nano-Pore Sequencing , by Region USD Million (2023-2028)
  • Table 161. South America Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2023-2028)
  • Table 162. South America Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 163. South America Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 164. South America Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 165. South America Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 166. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 167. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 168. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 169. Brazil Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 170. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 171. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 172. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 173. Argentina Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 174. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 175. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 176. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 177. Rest of South America Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 178. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2023-2028)
  • Table 179. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 180. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 181. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 182. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 183. China Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 184. China Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 185. China Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 186. China Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 187. Japan Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 188. Japan Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 189. Japan Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 190. Japan Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 191. India Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 192. India Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 193. India Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 194. India Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 195. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 196. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 197. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 198. South Korea Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 199. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 200. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 201. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 202. Taiwan Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 203. Australia Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 204. Australia Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 205. Australia Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 206. Australia Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 208. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 209. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 210. Rest of Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 211. Europe Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2023-2028)
  • Table 212. Europe Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 213. Europe Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 214. Europe Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 215. Europe Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 216. Germany Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 217. Germany Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 218. Germany Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 219. Germany Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 220. France Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 221. France Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 222. France Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 223. France Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 224. Italy Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 225. Italy Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 226. Italy Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 227. Italy Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 228. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 229. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 230. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 231. United Kingdom Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 232. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 233. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 234. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 235. Netherlands Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 236. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 237. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 238. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 239. Rest of Europe Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 240. MEA Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2023-2028)
  • Table 241. MEA Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 242. MEA Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 243. MEA Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 244. MEA Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 245. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 246. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 247. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 248. Middle East Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 249. Africa Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 250. Africa Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 251. Africa Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 252. Africa Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 253. North America Clinical Oncology Next Generation Sequencing (NGS), by Country USD Million (2023-2028)
  • Table 254. North America Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 255. North America Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 256. North America Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 257. North America Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 258. United States Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 259. United States Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 260. United States Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 261. United States Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 262. Canada Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 263. Canada Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 264. Canada Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 265. Canada Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 266. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Type USD Million (2023-2028)
  • Table 267. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Application USD Million (2023-2028)
  • Table 268. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Category USD Million (2023-2028)
  • Table 269. Mexico Clinical Oncology Next Generation Sequencing (NGS), by Technology USD Million (2023-2028)
  • Table 270. Clinical Oncology Next Generation Sequencing (NGS): by Type(USD/Units)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Clinical Oncology Next Generation Sequencing (NGS): by Type USD Million (2017-2022)
  • Figure 5. Global Clinical Oncology Next Generation Sequencing (NGS): by Application USD Million (2017-2022)
  • Figure 6. Global Clinical Oncology Next Generation Sequencing (NGS): by Category USD Million (2017-2022)
  • Figure 7. Global Clinical Oncology Next Generation Sequencing (NGS): by Technology USD Million (2017-2022)
  • Figure 8. South America Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 9. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 10. Europe Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 11. MEA Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 12. North America Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 13. Global Clinical Oncology Next Generation Sequencing (NGS): by Type USD/Units (2017-2022)
  • Figure 14. Global Clinical Oncology Next Generation Sequencing (NGS) share by Players 2022 (%)
  • Figure 15. Global Clinical Oncology Next Generation Sequencing (NGS) share by Players (Top 3) 2022(%)
  • Figure 16. Global Clinical Oncology Next Generation Sequencing (NGS) share by Players (Top 5) 2022(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 19. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 20. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Becton, Dickinson and Company (United States) Revenue: by Geography 2022
  • Figure 22. Oxford Nanopore Technologies (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. Oxford Nanopore Technologies (United Kingdom) Revenue: by Geography 2022
  • Figure 24. Qiagen (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Qiagen (Germany) Revenue: by Geography 2022
  • Figure 26. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 27. Myriad Genetics (United States) Revenue: by Geography 2022
  • Figure 28. Illumina (United States) Revenue, Net Income and Gross profit
  • Figure 29. Illumina (United States) Revenue: by Geography 2022
  • Figure 30. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2022
  • Figure 32. Perkin Elmer (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. Perkin Elmer (United Kingdom) Revenue: by Geography 2022
  • Figure 34. GATC Biotech (Germany) Revenue, Net Income and Gross profit
  • Figure 35. GATC Biotech (Germany) Revenue: by Geography 2022
  • Figure 36. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 37. Agilent Technologies (United States) Revenue: by Geography 2022
  • Figure 38. Global Clinical Oncology Next Generation Sequencing (NGS): by Type USD Million (2023-2028)
  • Figure 39. Global Clinical Oncology Next Generation Sequencing (NGS): by Application USD Million (2023-2028)
  • Figure 40. Global Clinical Oncology Next Generation Sequencing (NGS): by Category USD Million (2023-2028)
  • Figure 41. Global Clinical Oncology Next Generation Sequencing (NGS): by Technology USD Million (2023-2028)
  • Figure 42. South America Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 43. Asia Pacific Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 44. Europe Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 45. MEA Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 46. North America Clinical Oncology Next Generation Sequencing (NGS) Share (%), by Country
  • Figure 47. Global Clinical Oncology Next Generation Sequencing (NGS): by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Becton, Dickinson and Company (United States)
  • Oxford Nanopore Technologies (United Kingdom)
  • Qiagen (Germany)
  • Myriad Genetics (United States)
  • Illumina (United States)
  • F. Hoffmann-La Roche (Switzerland)
  • Perkin Elmer (United Kingdom)
  • GATC Biotech (Germany)
  • Agilent Technologies (United States)
Additional players considered in the study are as follows:
Caris Life Sciences (United States) , Macrogen (South Korea) , Life Technologies (United States) , DNASTAR (United States) , Biomatters (New Zealand) , Partek (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 187 Pages 81 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Clinical Oncology Next Generation Sequencing (NGS) Quantitative research analysis
Global Clinical Oncology Next Generation Sequencing (NGS) Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Thermo Fisher Scientific (United States), Becton, Dickinson and Company (United States), Oxford Nanopore Technologies (United Kingdom), Qiagen (Germany), Myriad Genetics (United States), Illumina (United States), F. Hoffmann-La Roche (Switzerland), Perkin Elmer (United Kingdom), GATC Biotech (Germany) and Agilent Technologies (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Emergence of Cost-Efficient Genome Sequencing" is seen as one of major influencing trends for Clinical Oncology Next Generation Sequencing (NGS) Market during projected period 2022-2028.
The Clinical Oncology Next Generation Sequencing (NGS) market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Clinical Oncology Next Generation Sequencing (NGS) Report?

Have a Query? Click Here

Other Related Reports

Protein Crystallization Comprehensive Study by Application (Silico Drug Design, Binding Site Determination, Membrane Protein Structure Analysis, Others), Industry Verticals (Biotechnology, Pharmaceut...
$ 3750
Bioprocess Analyzers Comprehensive Study by Type (Substrate Analysis, Metabolite Analysis, Concentration Detection), Application (Antibiotics, Recombinant Proteins, Biosimilars, Others), Technology T...
$ 3650
Viral Vector and Plasmid DNA Manufacturing Comprehensive Study by Type (Viral Vector {Retroviral, Adenoviral, Lentiviral, Adenoassociated and Other}, Plasmid DNA, Non-Viral Vector), Application (Canc...
$ 3650
Biohacking Comprehensive Study by Type (Digital Health, Nutrition, Fitness, Meditation, Pharmaceuticals), Application (Synthetic Biology, Genetic Engineering, Forensic Sciences, Others), Industry Ver...
$ 3650
Microscope Illumination Comprehensive Study by Type (Non-Fluorescence, Fluorescence), Application (General Microscope, Fluorescence Microscope, Endoscopy, Others), End-Users (Biology, Medical, Life S...
$ 3500
DNA Extractor Comprehensive Study by Type (Automated , Semi-automatic), Application (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other), Extraction Kit (DNA Extraction K...
$ 3350